Dr. Clarissa Mathias
Oncologist at NOB/Oncoclínicas, chair of the International Council of the American Society of Clinical Oncology (ASCO), president of the Brazilian Society of Clinical Oncology (SBOC).
Dr. Margaret Foti
Dr. Sergio Simon
Universidade de SP Medical School, 1973; specialty in Internal Medicine, Hematology and Clinical Oncology in the United States 1974-1980; doctorate at the Universidade de São Paulo, 2003; assistant professor of Oncology, UNIFESP 2008-2013; clinical oncologist at Hospital Israelita Albert Einstein and at Centro Paulista de Oncologia; member of SBOC, ASCO and ESMO.
Dr. Paulo Marcelo Gehm Hoff
Paulo Marcelo Gehm Hoff
A doctor through the Universidade de Brasília (1991); PHD and associate professor of Oncology at Universidade de São Paulo Medical School, where he is a Full Professor; Fellowship in Hematology and Oncology at MD Anderson Cancer Center. Currently General Director of the Instituto do Câncer de São Paulo “Octávio Frias de Oliveira” and member of the Board of Directors at ASCO and the Hospital das Clínicas.
Dr. Carlos Gil Moreira Ferreira
Carlos Gil Moreira Ferreira
Carlos Gil Ferreira, MD, PhD. Clinical oncologist, doctor in experimental oncology through Vrije Universiteit Medical Center, Amsterdam, Holland. President and scientific director of Instituto Oncoclínicas.
Dr. Manuel Hidalgo
Manuel Hidalgo, M.D., Ph.D. is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital. He is also the Hugh E. Luckey Distinguished Professor of Medicine at Weill Cornell Medical Collge. Dr. Hidalgo received his MD degree from the University of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health Science Center in San Antonio. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio, TX. Prior to this position he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to be Director of the Gastrointestinal Oncology Programm at the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor of Oncology. In 2009 he became Director of the Clinical Research Program at the Speanish National Cancer Center and Vicedirector of Translational Research in 2011. In 2015 he became the Chief of the Division of Hematology and Oncology anf Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the used of Avatar mouse models for cancer research and recently contributed to the development and approval of nab-paclitaxel for pancreatic cancer treatmemt. His current work focuses on strategies for personalize medicine and inmmunotherapy in pancreatic cancer.